公开(公告)号：US20240360510A1

公开(公告)日：2024-10-31

申请号：US18563450

申请日：2022-05-24

申请人： UNIVERSITE PARIS-SACLAY ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

发明人： Jérôme BOULIGAND ,  Isabelle Bourdeau ,  Fanny CHASSELOUP ,  André Lacroix ,  Peter KAMENICKÝ

IPC分类号： C12Q1/6883 ,  A61K45/00 ,  G01N33/68

CPC分类号： C12Q1/6883 ,  A61K45/00 ,  G01N33/6893 ,  C12Q2600/156 ,  G01N2333/90274 ,  G01N2800/04 ,  G01N2800/50

摘要： The present results show that KDM1A is a key epigenetic regulator of tissue-specific expression of GIP receptor and possibly of other receptors from the G-protein coupled receptor family in hormone-producing glands, and that its alteration leads to the development of aberrant overexpression of eutopic hormone receptors or expression of ectopic hormone receptors that lead to abnormal steroidogenesis. They also show that loss of expression of KDM1A is likely to be the initiating event that trigger the abnormal cell proliferation leading to the development of tissue lesions in adrenal and possibly in other endocrine tissues (notably in the adrenal glands). The present invention therefore proposes to detect altered expression of KDM1A in the genome of subjects, in order to diagnose a genetic predisposition to an endocrine disease and/or to an endocrine hyperplasia. On another hand, the present results suggest that the physiological eutopic GIP receptor expression in the pancreas may be also epigenetically regulated by KDM1A. This expression could be pharmacologically targeted by KDM1A inhibitors so as to treat patients suffering from diabetes mellitus and other metabolic diseases.

公开(公告)号：US20240358760A1

公开(公告)日：2024-10-31

申请号：US18671662

申请日：2024-05-22

申请人： NantBio, Inc.

发明人： Krsto Sbutega ,  Peter Sieling ,  Adam D. Lazar ,  Kayvan Niazi

IPC分类号： A61K35/17 ,  A61K45/00 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K45/05 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2818 ,  C12N5/0636 ,  C12N2501/20

摘要： Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.

公开(公告)号：US20240342084A1

公开(公告)日：2024-10-17

申请号：US18751924

申请日：2024-06-24

申请人： Donaghys Limited

发明人： KAREN YERITSYAN

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K45/00 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44

CPC分类号： A61K9/08 ,  A61K9/0014 ,  A61K45/00 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44

摘要： Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

公开(公告)号：US12109245B2

公开(公告)日：2024-10-08

申请号：US16580826

申请日：2019-09-24

申请人： LABORATOIRES EXPANSCIENCE

发明人： Alex Saunois ,  Caroline Baudouin ,  Sophie Leclere-Bienfait ,  Sebastien Garnier ,  Philippe Msika

IPC分类号： A61K8/49 ,  A23L33/105 ,  A61K8/368 ,  A61K8/9789 ,  A61K31/05 ,  A61K31/197 ,  A61K31/198 ,  A61K31/201 ,  A61K31/341 ,  A61K31/42 ,  A61K31/57 ,  A61K31/585 ,  A61K31/715 ,  A61K31/717 ,  A61K33/30 ,  A61K36/28 ,  A61K36/31 ,  A61K36/48 ,  A61K36/54 ,  A61K36/899 ,  A61K38/00 ,  A61K45/00 ,  A61Q19/08

CPC分类号： A61K36/31 ,  A23L33/105 ,  A61K8/368 ,  A61K8/498 ,  A61K8/9789 ,  A61K31/05 ,  A61K31/197 ,  A61K31/198 ,  A61K31/201 ,  A61K31/341 ,  A61K31/42 ,  A61K31/57 ,  A61K31/585 ,  A61K31/715 ,  A61K31/717 ,  A61K33/30 ,  A61K36/28 ,  A61K36/48 ,  A61K36/54 ,  A61K36/899 ,  A61K38/00 ,  A61K45/00 ,  A61Q19/08 ,  A61K2800/805

摘要： The invention relates to an extract of aerial parts of Maca rich in polyphenols, and also to a composition comprising such an extract and, where appropriate, a suitable excipient. The invention also relates to a process for extracting an extract of aerial parts of Maca rich in polyphenols, and also to the extract that can be obtained by means of said process. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths and/or for use thereof in preventing and/or treating vascular disorders. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which comprises the administration of such a composition or of such an extract.

公开(公告)号：US20240307463A1

公开(公告)日：2024-09-19

申请号：US18737799

申请日：2024-06-07

申请人： The University of Tokyo

发明人： Kenya Honda ,  Koji Atarashi ,  Kikuji Itoh ,  Takeshi Tanoue

IPC分类号： A61K35/742 ,  A01K67/0275 ,  A61K9/00 ,  A61K9/48 ,  A61K35/00 ,  A61K35/74 ,  A61K39/00 ,  A61K39/08 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  C12Q1/689 ,  G01N33/50

CPC分类号： A61K35/742 ,  A01K67/0275 ,  A61K9/0053 ,  A61K9/48 ,  A61K35/74 ,  A61K39/0008 ,  A61K39/08 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  C12Q1/689 ,  G01N33/505 ,  A01K2267/0325 ,  A61K35/00 ,  A61K2039/52 ,  A61K2039/542 ,  A61K2039/55594 ,  A61K2039/57 ,  C12Q2600/158 ,  G01N2333/33 ,  G01N2500/10

摘要： It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

公开(公告)号：US12011390B2

公开(公告)日：2024-06-18

申请号：US17524610

申请日：2021-11-11

申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

发明人： Andrew Schieber ,  Linda Thai ,  Malik Kahook

IPC分类号： A61F9/00 ,  A61K9/00 ,  A61K45/00

CPC分类号： A61F9/0008 ,  A61K9/0051 ,  A61K45/00

摘要： A lacrimal drug delivery device includes a reservoir configured to hold a drug. The reservoir is moveable between a relaxed state and an expanded state. A connector is fluidly coupled to the reservoir and a lumen is formed in the connector wherein the drug is configured to flow from the reservoir to an delivery site through the lumen. A hydrogel is within the lumen and configured to absorb the drug from the reservoir and deliver the drug from the lumen at the delivery site. The hydrogel includes a first section which absorbs the drug at a first rate of absorption. A delivery guide is detachably coupled to the reservoir to deliver the reservoir into a lacrimal sac of a patient.

公开(公告)号：US20240165192A1

公开(公告)日：2024-05-23

申请号：US18410200

申请日：2024-01-11

申请人： GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.

发明人： Gang QIN ,  Jinduo YUAN ,  Lu JIANG ,  Chubing TAN ,  Lili SHI ,  Cao LV ,  Leilei CHEN

IPC分类号： A61K38/07 ,  A61K31/537 ,  A61K45/00 ,  A61K47/50 ,  A61K47/68 ,  C07K16/28 ,  C07K16/32

CPC分类号： A61K38/07 ,  A61K31/537 ,  A61K45/00 ,  A61K47/50 ,  A61K47/6851 ,  C07K16/2863 ,  C07K16/32 ,  A61K2039/505

摘要： The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

公开(公告)号：US20240165111A1

公开(公告)日：2024-05-23

申请号：US18502460

申请日：2023-11-06

申请人： INTRA-CELLULAR THERAPIES, INC.

发明人： Wei YAO ,  Peng LI ,  Robert DAVIS ,  Sharon MATES ,  Kimberly VANOVER ,  Gretchen SNYDER

IPC分类号： A61K31/4985 ,  A61K9/00 ,  A61K9/16 ,  A61K31/445 ,  A61K45/00 ,  A61K45/06 ,  A61P25/00 ,  C07D241/40 ,  C07D471/16

CPC分类号： A61K31/4985 ,  A61K9/0019 ,  A61K9/16 ,  A61K31/445 ,  A61K45/00 ,  A61K45/06 ,  A61P25/00 ,  C07D241/40 ,  C07D471/16

摘要： The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine Di and D2 receptor signaling system, and/or the wopioid receptor.

公开(公告)号：US11970522B2

公开(公告)日：2024-04-30

申请号：US17006219

申请日：2020-08-28

申请人： The University of British Columbia

发明人： Neil R. Cashman ,  Steven S. Plotkin

IPC分类号： C07K7/00 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K38/17 ,  A61K39/00 ,  A61K47/64 ,  A61K51/10 ,  A61P25/28 ,  C07K5/113 ,  C07K5/117 ,  C07K7/64 ,  C07K14/00 ,  C07K14/47 ,  C07K16/18 ,  G01N33/68 ,  A61K38/05 ,  A61K38/07 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61K49/18 ,  A61K51/08 ,  A61L27/22 ,  A61L27/34 ,  A61L29/08 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/103 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K16/00 ,  G01N33/50

CPC分类号： C07K14/4711 ,  A61K39/0008 ,  A61K47/643 ,  A61K47/646 ,  A61K51/1018 ,  A61P25/28 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/64 ,  C07K16/18 ,  G01N33/6896 ,  A61K38/00 ,  A61K38/05 ,  A61K38/07 ,  A61K38/08 ,  A61K38/12 ,  A61K39/00 ,  A61K39/0007 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6081 ,  A61K45/05 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6921 ,  A61K49/1818 ,  A61K51/088 ,  A61K51/10 ,  A61K2300/00 ,  A61L27/227 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/101 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K16/00 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/387

摘要： The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

公开(公告)号：US11931417B2

公开(公告)日：2024-03-19

申请号：US17173783

申请日：2021-02-11

申请人： Nansha Biologics (Hong Kong) Limited

发明人： Kuo-Ming Yu ,  Qui-Lim Choo ,  Manson Fok ,  Johnson Yiu-Nam Lau

IPC分类号： A61K47/60 ,  A61K9/00 ,  A61K38/00 ,  A61K38/20 ,  A61K45/00 ,  A61K45/06 ,  C07K14/54

CPC分类号： A61K47/60 ,  A61K9/0019 ,  A61K38/2073 ,  A61K45/00 ,  A61K45/06 ,  C07K14/5431 ,  A61K38/00

摘要： Methods are provided for producing a PEGylated interleukin 11 (IL-11) by treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.